文献速递病毒性肝炎

核心I97L突变联合P79Q与慢性乙肝持续低HBV DNA及HBsAg清除相关

Core I97L mutation in conjunction with P79Q is associated with persistent low HBV DNA and HBs antigen clearance in patients with chronic hepatitis B.
PubMed 文献 · Clin Microbiol Infect · 2016-12-18

本研究对33例C基因型慢性乙肝患者按HBV DNA和ALT水平分组比较全长HBV序列,发现核心突变I97L在三组间分布差异显著;随后在82例患者中评估I97L及P79Q,Kaplan-Meier分析显示携带I97L者持续低HBV DNA和HBsAg清除累积发生率更高,联合P79Q者更高。

要点

  • 核心I97L突变在持续低HBV DNA且ALT正常患者中发生率更高。
  • 携带I97L者持续低HBV DNA和HBsAg清除的累积发生率显著更高。
  • 联合P79Q突变者上述累积发生率进一步升高。

核心结论

  • 在慢性乙肝患者中,检测I97L及附加突变P79Q有助于预测持续低HBV DNA、ALT正常及HBsAg清除。

研究设计与样本

  • 先对33例C基因型慢性乙肝患者按HBV DNA和ALT水平分三组比较全长HBV序列,再在82例慢性乙肝患者中评估I97L和P79Q,用Kaplan-Meier法比较累积发生率。

主要发现

  • 核心突变I97L发生率在A组为30%(3/10)、B组为36.4%(4/11)、C组为83.3%(10/12),组间差异显著(p=0.021)。
  • 携带I97L者持续低HBV DNA累积发生率显著高于野生型I97者(p=0.003)。
  • 携带I97L者HBsAg清除累积发生率显著高于野生型I97者(p=0.016)。
  • 携带P79Q者上述累积发生率更高。

临床怎么用

  • 对慢性乙肝患者可检测I97L及P79Q突变,辅助预测持续低HBV DNA、ALT正常和HBsAg清除。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: When considering treatment for chronic hepatitis B (CHB), it is important to discriminate between patients with persistent low HBV DNA and patients with active hepatitis, who may proceed to cirrhosis. In this study, we sought to identify mutations in patients expected to have persistent low HBV DNA and ultimately exhibit clearance of hepatitis B surface antigen (HBsAg). METHODS: Serum samples were obtained from 33 CHB genotype C patients, divided based on HBV DNA and alanine aminotransferase (ALT) levels following observation for >2 years: Group A (n=10), transient HBV DNA ≥5.0 log copies/mL and ALT ≥120 IU/L; Group B (n=11), persistent HBV DNA <5.0 and ALT <60; and Group C (n=12), persistent HBV DNA <4.0 and ALT <30. Full-length HBV sequences were compared among groups. Subsequently, 82 patients with CHB were evaluated for the I97L mutation and the additional mutation P79Q. We compared cumulative incidences of persistent low HBV DNA and HBsAg clearance in patients with or without I97L and P79Q by the Kaplan-Meier method. RESULTS: Incidence of Core mutation I97L differed significantly among groups: A, 30% (3/10); B, 36.4% (4/11); C, 83.3% (10/12) (p = 0.021). Cumulative incidences of persistent low HBV DNA and HBsAg clearance were significantly higher in patients with I97L than in those with wild-type I97 (p = 0.003 and p = 0.016, respectively), and even higher in those with P79Q. CONCLUSIONS: In patients with CHB, measurement of I97L and additional mutation P79Q would be useful for predicting persistent low HBV DNA, normal ALT, and HBsAg clearance.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Honda T, Ishigami M, Ishizu Y, et al. Core I97L mutation in conjunction with P79Q is associated with persistent low HBV DNA and HBs antigen clearance in patients with chronic hepatitis B. Clin Microbiol Infect. 2016. PMID: 27998820. doi:10.1016/j.cmi.2016.12.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。